The in vivo efficacies of amikacin, ceftazidime, and their combination were evaluated in experimental aortic valve endocarditis due to Pseudomonas aeruginosa. Eighty catheterized rabbits were infected with a P. aeruginosa strain susceptible to both amikacin and ceftazidime and then received no therapy (controls), amikacin (15 mg/kg per day), ceftazidime (100 mg/kg per day), or amikacin-ceftazidime. Amikacin Morrison, Chemotherapy [Basel], in press). In that study, the amikacin-ceftazidime regimen was significantly more effective than the single-drug regimens in reducing the mean vegetation titers of P. aeruginosa and reducing the prevalence of bacteriologic relapses after therapy was terminated. In the current study, we examined this synergistic combination in experimental left-sided P. aeruginosa endocarditis, the most refractory syndrome in human cases (16 identification, serotyping, and resistance to rabbit serum have been previously described (5).Antibiotic susceptibility testing. MICs and MBCs of amikacin and ceftazidime were determined by the broth macrodilution technique (13) with Mueller-Hinton broth (MHB; BBL Microbiology Systems, Cockeysville, Md.). MHB has a concentration of 0.5 mg/100 ml of magnesium and 3.2 mg/100 ml of calcium. Logarithmic-growth-phase cultures were used to prepare inocula of PA-96 at -5 x 105 or -5 x 107 CFU/ml. The -107 inoculum was utilized to determine the antibiotic susceptibility at bacterial densities likely to be encountered within cardiac vegetations in vivo (1). The MIC was defined as the lowest antibiotic concentration causing no visible turbidity. The MBCs were determined by subculturing 10 ,ul from each clear tube onto antibiotic-free MH agar plates. The MBC was the lowest concentration of antibiotic that effected -99.9% reduction of the original inoculum. The MICs and MBCs of selected amikacin-or ceftazidime-resistant organisms isolated from endocardial vegetations were also determined for gentamicin, kanamycin, moxalactam, cefoperazone, azlocillin, mezlocillin, and ciprofloxacin (inoculum size, -5 x 105 CFU/ml).In vitro bactericidal interaction testing. Bactericidal interactions of ceftazidime and amikacin against PA-96 were examined with the time-kill assay system. As before, a logarithmic-phase inoculum of either -5 x 105 or -5 x 107 CFU/ml was used. The final antibiotic concentrations tested were amikacin alone at one-half the MBC, ceftazidime alone at one-half the MBC, or amikacin-ceftazidime, each drug at one-quarter its MBC. A synergistic interaction was considered present when the amikacin-ceftazidime combination caused a -2 log10 decrease in CFU per milliliter at 24 h in comparison with the more active single agent (10).